Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

Sept. 19 Quick Takes: RNA editing company Airna emerges with $30M round led by Arch

Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek 

September 20, 2023 12:07 AM UTC

Airna Corp. Inc. raised $30 million in an undisclosed venture round led by Arch Venture Partners, with participation from ND Capital, Fast Track Initiative (FTI), Novalis and Codon Capital. The Cambridge, Mass.-based company, which has research operations in Germany, develops oligonucleotides that bind target RNA sequences and recruit ADAR deaminase enzymes for targeted transcript editing via its RESTORE+ platform, based on technology from co-founders Thorsten Stafforst at University of Tübingen and Jin Billy Li at Stanford University. Airna’s lead program is in preclinical development for the genetic disease alpha-1 antitrypsin deficiency (AATD), and subsequent programs will target prevalent diseases.

New VC firm age1 launched with a focus on pre-seed and seed funding for longevity-focused biotechs. The firm, which had a first close of $35 million, was co-founded by Laura Deming, founder of The Longevity Fund, and Alex Colville, an investor who studied the biology of aging at Stanford University...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article